Interaction analysis of high-risk pathological features on adjuvant chemotherapy survival benefit in stage II colon cancer patients: a multi-center, retrospective study

被引:0
作者
Li, Kexuan [1 ]
Zhao, Fuqiang [2 ]
Guo, Yuchen [3 ]
Wu, Qingbin [4 ]
Luo, Shuangling [5 ,6 ,7 ]
Zhang, Junling [8 ]
Li, Heli [9 ]
Hu, Shidong [10 ]
Wu, Bin [1 ]
Lin, Guole [1 ]
Qiu, Huizhong [1 ]
Niu, Beizhan [1 ]
Sun, Xiyu [1 ]
Xu, Lai [1 ]
Lu, Junyang [1 ]
Du, Xiaohui [10 ]
Wang, Zheng [9 ]
Wang, Xin [8 ]
Kang, Liang [5 ,6 ,7 ]
Wang, Ziqiang [4 ]
Wang, Quan [3 ]
Liu, Qian [2 ]
Xiao, Yi [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Gen Surg, Div Colorectal Surg, 1 Shuai Fu Yuan Rd, Beijing 100730, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp,Dept Diagnost Radiol, 17 Panjiayuan Nanli, Beijing 100021, Peoples R China
[3] First Hosp Jilin Univ, Gen Surg Ctr, Dept Gastrointestinal Surg, 1 Xin Min Ave, Changchun 130021, Peoples R China
[4] Sichuan Univ, West China Hosp, Colorectal Canc Ctr, Dept Gen Surg, 37 Guo Xue Xiang, Chengdu 610041, Peoples R China
[5] Sun Yat sen Univ, Affiliated Hosp 6, Dept Gen Surg Colorectal Surg, 26 Yuan Cun Er Heng Rd, Guangzhou 510655, Peoples R China
[6] Sun Yat sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal & Pelv Floor Dis, 26 Yuan Cun Er Heng Rd, Guangzhou 510655, Peoples R China
[7] Sun Yat sen Univ, Affiliated Hosp 6, Biomed Innovat Ctr, 26 Yuan Cun Er Heng Rd, Guangzhou 510655, Peoples R China
[8] Peking Univ First Hosp, Dept Gastrointestinal Surg, 8 Xi Shi Ku St, Beijing 100034, Peoples R China
[9] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, 1277 Jiefang Ave, Wuhan 430022, Peoples R China
[10] Chinese Peoples Liberat Army PLA Gen Hosp, Med Ctr 1, Dept Gen Surg, 28 Fu Xing Rd, Beijing 100853, Peoples R China
基金
中国国家自然科学基金;
关键词
Colon cancer; High-risk pathological features; Adjuvant chemotherapy; PERINEURAL INVASION; PREDICTIVE FACTOR; PROGNOSTIC-FACTOR; OXALIPLATIN; FLUOROURACIL; LEUCOVORIN; OUTCOMES; THERAPY; TRIAL;
D O I
10.1186/s12885-023-11196-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background We aimed to analyze the benefit of adjuvant chemotherapy in high-risk stage II colon cancer patients and the impact of high-risk factors on the prognostic effect of adjuvant chemotherapy. Methods This study is a multi-center, retrospective study, A total of 931 patients with stage II colon cancer who underwent curative surgery in 8 tertiary hospitals in China between 2016 and 2017 were enrolled in the study. Cox proportional hazard model was used to assess the risk factors of disease-free survival (DFS) and overall survival (OS) and to test the multiplicative interaction of pathological factors and adjuvant chemotherapy (ACT). The additive interaction was presented using the relative excess risk due to interaction (RERI). The Subpopulation Treatment Effect Pattern Plot (STEPP) was utilized to assess the interaction of continuous variables on the ACT effect. Results A total of 931 stage II colon cancer patients were enrolled in this study, the median age was 63 years old (interquartile range: 54-72 years) and 565 (60.7%) patients were male. Younger patients (median age, 58 years vs 65 years; P < 0.001) and patients with the following high-risk features, such as T4 tumors (30.8% vs 7.8%; P < 0.001), grade 3 lesions (36.0% vs 22.7%; P < 0.001), lymphovascular invasion (22.1% vs 6.8%; P < 0.001) and perineural invasion (19.4% vs 13.6%; P = 0.031) were more likely to receive ACT. Patients with perineural invasion showed a worse OS and marginally worse DFS (hazardous ratio [HR] 2.166, 95% confidence interval [CI] 1.282-3.660, P = 0.004; HR 1.583, 95% CI 0.985-2.545, P = 0.058, respectively). Computing the interaction on a multiplicative and additive scale revealed that there was a significant interaction between PNI and ACT in terms of DFS (HR for multiplicative interaction 0.196, p = 0.038; RERI, -1.996; 95%CI, -3.600 to -0.392) and OS (HR for multiplicative interaction 0.112, p = 0.042; RERI, -2.842; 95%CI, -4.959 to -0.725). Conclusions Perineural invasion had prognostic value, and it could also influence the effect of ACT after curative surgery. However, other high-risk features showed no implication of efficacy for ACT in our study.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database
    Yu, Qiao
    Li, Zhigui
    Liu, Yuqing
    Luo, Yichen
    Fan, Jingya
    Xie, Peijun
    Cao, Xiaoman
    Chen, Xingyu
    Wang, Xiaodong
    CURRENT ONCOLOGY, 2023, 30 (01) : 949 - 958
  • [42] Adjuvant Chemotherapy for High-Risk Stage II Colon Cancer: A Population-Based Study
    Butare, Annmarie
    Sutton, Tia
    Kantzler, Elizabeth
    Kennedy, Katie N.
    Tumin, Dmitry
    Honaker, Michael D.
    JOURNAL OF GASTROINTESTINAL CANCER, 2025, 56 (01)
  • [43] Are pathological high-risk features in locally advanced rectal cancer a useful selection tool for adjuvant chemotherapy?
    Swets, Marloes
    Kuppen, Peter J. K.
    Blok, Erik J.
    Gelderblom, Hans
    van de Velde, Cornelis J. H.
    Nagtegaal, Iris D.
    EUROPEAN JOURNAL OF CANCER, 2018, 89 : 1 - 8
  • [44] Efficacy and Safety of Capecitabine and Oxaliplatin (CapOX) as an Adjuvant Therapy in Japanese for Stage II/III Colon Cancer in a Group at High Risk of Recurrence in Retrospective Study
    Osawa, Hiroshi
    Handa, Naoko
    Minakata, Kunihiko
    ONCOLOGY RESEARCH, 2015, 22 (5-6) : 325 - 331
  • [45] Feasibility Study of a Modified XELOX Adjuvant Chemotherapy for High-Recurrence Risk Patients With Operated Stage III Colon Cancer
    Peng, Jianhong
    Li, Weihao
    Fan, Wenhua
    Zhou, Wenhao
    Zhu, Ying
    Li, Xueying
    Pan, Zhizhong
    Lin, Xiaoping
    Lin, Junzhong
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [46] Clinical Implications of Mismatch Repair Status in Patients With High-risk Stage II Colon Cancer
    Baek, Dong Won
    Kang, Byung Woog
    Lee, Soo Jung
    Kim, Hye Jin
    Park, Su Yeon
    Park, Jun Seok
    Choi, Gyu Seog
    Baek, Jin Ho
    Kim, Jong Gwang
    IN VIVO, 2019, 33 (02): : 649 - 657
  • [47] Benefit of adjuvant chemotherapy in high-risk colon cancer: A 17-year population-based analysis of 6131 patients with Union for International Cancer Control stage II T4N0M0 colon cancer
    Teufel, Andreas
    Gerken, Michael
    Fuerst, Alois
    Ebert, Matthias
    Hohenthanner, Ina
    Klinkhammer-Schalke, Monika
    EUROPEAN JOURNAL OF CANCER, 2020, 137 : 148 - 160
  • [48] Postoperative chemotherapy improves survival in patients with resected high-risk Stage II colorectal cancer: results of a systematic review and meta-analysis
    Simillis, C.
    Singh, H. K. S. I.
    Afxentiou, T.
    Mills, S.
    Warren, O. J.
    Smith, J. J.
    Riddle, P.
    Adamina, M.
    Cunningham, D.
    Tekkis, P. P.
    COLORECTAL DISEASE, 2020, 22 (10) : 1231 - 1244
  • [49] High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer
    Ji Soo Park
    Hong Jae Chon
    Hei-Cheul Jeung
    Sang Joon Shin
    Sun Young Rha
    Joong Bae Ahn
    Kang Young Lee
    Nam Kyu Kim
    Hyun Cheol Chung
    Journal of Cancer Research and Clinical Oncology, 2016, 142 : 2051 - 2059
  • [50] A national evaluation of the predictors of compliance and survival from adjuvant chemotherapy in high-risk stage II colon cancer: A National Cancer Database (NCDB) analysis
    de Paula, Thais Reif
    Gorroochurn, Prakash
    Haas, Eric M.
    Keller, Deborah S.
    SURGERY, 2022, 172 (03) : 859 - 868